Presentation TCT 2016 Accounting for the Risk of Competing Events Presenter: Scott Berry, Stuart J. Pocock, Peter Juni October 30, 2016
Presentation TCT 2016 Analyzing Repeat Events Presenter: Scott Berry, Stuart J. Pocock, Eugene H. Blackstone October 30, 2016
Presentation TCT 2016 Limitations of Composite Endpoints and Strategies for Hierarchical Testing Presenter: Scott Berry, Stuart J. Pocock, Jan G. P. Tijssen October 30, 2016
Presentation TCT 2016 Strengths and Limitations of Meta-analysis: Standard, Network and Bayesian Techniques, and the Value of Individual Patient-level Data Pooling Presenter: Ori Ben-Yehuda, Tullio Palmerini, Giuseppe Biondi-Zoccai October 30, 2016
Presentation TCT 2016 When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions? Presenter: Eugene H. Blackstone, Robert W. Yeh, Robert A. Harrington October 30, 2016
Presentation TCT 2016 Can Propensity and Instrumental Variable Methods Overcome the Limitations of Observational Databases: Lessons From TRANSLATE-ACS Presenter: Eugene H. Blackstone, Robert W. Yeh, Tracy Y. Wang October 30, 2016
Presentation TCT 2016 Comparison of Propensity Score Methods and Covariate Adjustment in Observational Studies: Similarities and Differences Presenter: Eugene H. Blackstone, Robert W. Yeh, Stuart J. Pocock October 30, 2016
Presentation TCT 2016 Importance of Unmeasured Confounders in Observational Registries: ASCERT and Other Examples Presenter: Eugene H. Blackstone, Robert W. Yeh, Kirk N. Garratt October 30, 2016
Presentation TCT 2016 Value and Hazards of Subgroup Analysis: the SYNTAX to EXCEL Case Study Presenter: Peter Juni, E. Magnus Ohman, Ori Ben-Yehuda October 30, 2016
Presentation TCT 2016 Clinical Trial Interpretation: Relative vs Absolute Differences Presenter: Peter Juni, E. Magnus Ohman, John A. Bittl October 30, 2016
Presentation TCT 2016 Levels of Evidence: Single-center vs Multicenter Trials Presenter: Peter Juni, E. Magnus Ohman, Roxana Mehran October 30, 2016
Presentation TCT 2016 Should Clinical Trial Interpretation Be Dominated by A P Value of 0.05 for the Primary Endpoint? Presenter: Peter Juni, E. Magnus Ohman, Gregg W. Stone October 30, 2016
Presentation TCT 2016 The Extraordinary Frustration of Converting Meaningful Clinical Trial Results (and Guidelines) Into Changes in Clinical Practice Presenter: Roxana Mehran, Pascal Vranckx October 30, 2016
Presentation TCT 2016 Quality-of-Life Measures as Valid Clinical Surrogates and Primary Endpoints in Randomized Trials: Why the Resistance? Presenter: Roxana Mehran, Pascal Vranckx, John A. Spertus October 30, 2016
Presentation TCT 2016 Issues With Non-inferiority Trials: Choosing the Margin and Comparator; Creep, Noise, and More Presenter: Roxana Mehran, Pascal Vranckx, Sanjay Kaul October 30, 2016
Presentation TCT 2016 Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in A Bayesian Framework! Presenter: Roxana Mehran, Pascal Vranckx, Scott Berry October 30, 2016
Presentation TCT 2016 Debate: What Is the Optimal Study Design for Maximizing Trial Efficiency, Success, and Interpretability? Adaptive Design in a Frequentist Framework! Presenter: Roxana Mehran, Pascal Vranckx, Stuart J. Pocock October 30, 2016
Presentation TCT 2016 How to Be a Key Investigator? Its Not Just Quantity- Quality Is Top Priority Presenter: David A. Cox, Thomas D. Stuckey October 30, 2016
Presentation TCT 2016 Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington October 30, 2016
Presentation TCT 2016 Quality and Compliance in Research: The Crucial First Step Presenter: David A. Cox, Thomas D. Stuckey, Kate Dalton October 30, 2016